search button

Association and interaction between model for end‑stage liver disease score and minimally invasive treatment with regard to mortality of patients with hepatitis B virus‑associated hepatocellular carcinoma and portal vein tumor thrombi

  • Authors:
    • Mengge Li
    • Yalin Zhao
    • Xiaoli Liu
    • Zhibo Dang
    • Xinhui Wang
    • Yuyong Jiang
    • Zhiyun Yang

  • View Affiliations

  • Published online on: October 17, 2018     https://doi.org/10.3892/ol.2018.9590
  • Pages: 119-126

  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The development of minimally invasive treatment over the last two decades has had a great impact on hepatitis B virus (HBV)‑associated primary liver cancer. The model for end‑stage liver disease (MELD) score is the optimal evaluated parameter for mortality in patients with end‑stage liver disease. However, the association between MELD score and minimally invasive treatment with regard to the mortality of patients with HBV‑associated hepatocellular carcinoma (HCC) with a portal vein tumor thrombus (PVTT) remains unclear. In the present study, a total of 173 patients who had been diagnosed with HBV‑associated HCC and PVTT in the Beijing Ditan Hospital (Beijing, China), between January 2012 and January 2015, were screened. Follow‑up was performed to observe the survival time and collect information on the demographic characteristics and associated clinical indicators present in the cohort. The patient's age, sex, laboratory parameters and the use of minimally invasive treatment were analyzed with SPSS 20.0 software. Independent risk factors for mortality were screened by Cox regression analysis. Logistic regression indicated that there was an interaction between the MELD score and minimally invasive treatment. In addition, a MELD score ≤17.85 was associated with a lower mortality rate subsequent to minimally invasive treatment.
View Figures
View References

Related Articles

Journal Cover

January-2019
Volume 17 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Li M, Zhao Y, Liu X, Dang Z, Wang X, Jiang Y and Yang Z: Association and interaction between model for end‑stage liver disease score and minimally invasive treatment with regard to mortality of patients with hepatitis B virus‑associated hepatocellular carcinoma and portal vein tumor thrombi. Oncol Lett 17: 119-126, 2019
APA
Li, M., Zhao, Y., Liu, X., Dang, Z., Wang, X., Jiang, Y., & Yang, Z. (2019). Association and interaction between model for end‑stage liver disease score and minimally invasive treatment with regard to mortality of patients with hepatitis B virus‑associated hepatocellular carcinoma and portal vein tumor thrombi. Oncology Letters, 17, 119-126. https://doi.org/10.3892/ol.2018.9590
MLA
Li, M., Zhao, Y., Liu, X., Dang, Z., Wang, X., Jiang, Y., Yang, Z."Association and interaction between model for end‑stage liver disease score and minimally invasive treatment with regard to mortality of patients with hepatitis B virus‑associated hepatocellular carcinoma and portal vein tumor thrombi". Oncology Letters 17.1 (2019): 119-126.
Chicago
Li, M., Zhao, Y., Liu, X., Dang, Z., Wang, X., Jiang, Y., Yang, Z."Association and interaction between model for end‑stage liver disease score and minimally invasive treatment with regard to mortality of patients with hepatitis B virus‑associated hepatocellular carcinoma and portal vein tumor thrombi". Oncology Letters 17, no. 1 (2019): 119-126. https://doi.org/10.3892/ol.2018.9590